|Tested species reactivity||Human, Rat|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Purification||Ammonium sulfate precipitation|
|Storage buffer||HEPES with 0.15M NaCl, 0.01% BSA, 50% glycerol|
|Contains||0.03% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 1 publications below|
A suggested positive control for this product is K562 cells.
NFKB1. or NFKB2. is bound to REL., RELA, or RELB. to form the NFKB complex. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NFKB. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008 or NFKBIB, MIM 604495), which inactivate NFKB by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664, or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NFKB complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease.
LF-PA0062 was used in immunocytochemistry to investigate the neuroprotective effect of 11-dehydrosinulariolide in an in vitro model of Parkinson disease
|Chen WF,Chakraborty C,Sung CS,Feng CW,Jean YH,Lin YY,Hung HC,Huang TY,Huang SY,Su TM,Sung PJ,Sheu JH,Wen ZH||Naunyn-Schmiedeberg's archives of pharmacology (385:265)||2012|